Fosamax_Plus_D: profile and news
Merck profits edge ahead in fourth quarter Feb 1, 2006
...although the osteoporosis drug Fosamax (alendronate) declined 5% to $789 million, with the launch of a new formulation (Fosamax Plus D/Fosavance) failing to ... - Pharma Times (subscription),
Merck Earnings Top Estimates Jan 31, 2006
12% to $819 million; sales of blood-pressure drugs Cozaar and Hyzaar rose 2% to $782 million; sales osteoporosis medication Fosamax and Fosamax Plus D fell 5 ... - TheStreet.com
Merck Announces Strong Full-Year and Fourth-Quarter 2005 Earnings ... Jan 31, 2006
FOSAMAX and FOSAMAX PLUS D (launching under the name FOSAVANCE throughout the European Union) together remain the most-prescribed medicine worldwide for the ... - TMCnet
Merck profits edge ahead in fourth quarter Feb 1, 2006
...although the osteoporosis drug Fosamax (alendronate) declined 5% to $789 million, with the launch of a new formulation (Fosamax Plus D/Fosavance) failing to ... - Pharma Times (subscription),
Don't Forget Your "D" Oct 7, 2005
Women taking prescription medicines to ward off osteoporosis may be interested to learn that the FDA has approved Fosamax Plus D (alendronate sodium ... - Saturday Evening Post,
Staying power Aug 18, 2005
Merck announced in June that Wilson Merck is gearing up to participate in post-launch and supply activity for the company's osteoporosis drug, Fosamax Plus D. ... - Wilson Daily Times (subscription),
